Top 5 Biotech Penny Stocks Worth Watching

buy penny stocks, penny stocks, penny stock alerts, hot penny stocks, hottest penny stocks, best penny stocks



Celldex Therapeutics (Nasdaq: CLDX)

Open: 2.34
Bid: 2.30 x 900
Ask: 2.31 x 700
1y Target Est: 9.00
52wk Range: 2.05 – 4.70
Avg Vol (3m): 235,960
Market Cap: 101.54M

Celldex Therapeutics, Inc. (CLDX) said on Monday a mid-stage trial of its experimental brain cancer vaccine improved survival in patients with a specific genetic mutation.

Geron (Nasdaq: GERN)
Open: 1.49
Bid: 1.52 x 3700
Ask: 1.53 x 4300
1y Target Est: 5.50
52wk Range: 1.41 – 6.34
Avg Vol (3m): 1,623,140
Market Cap: 199.84M

Geron Corporation (GERN), considered the recognized leader in embryonic stem cell research, received the first green light to conduct a clinical trial utilizing that technology. Geron used its stem cell technology to devise a treatment for spinal cord industries (SCI). GERN’s market cap approached a billion dollars at points over the past couple of years.

Micromet (Nasdaq: MITI)
Open: 5.18
Bid: 5.15 x 500
Ask: 5.16 x 2800
1y Target Est: 8.56
52wk Range: 4.13 – 8.63
Avg Vol (3m): 548,105
Market Cap: 474.95M

Micromet, Inc. (MITI), is a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer. MITI announced today that they will participate in the 2011 Piper Jaffray Health Care conference in New York City.

Oncothyreon (Nasdaq: ONTY)
Open: 6.93
Bid: 6.69 x 200
Ask: 6.71 x 300
1y Target Est: 8.83
52wk Range: 2.99 – 11.59
Avg Vol (3m): 534,685
Market Cap: 285.97M

Oncothyreon, Inc. (ONTY) announced the presentation of data from two Phase 1/2 trials of PX-866, an irreversible, pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor. PX-866 is a small molecule, pan inhibitor of the PI-3K/PTEN/AKT pathway, a critical cell signaling pathway that is activated in many types of human cancer.

Vical (Nasdaq: VICL)
Open: 3.45
Bid: 3.51 x 500
Ask: 3.52 x 1400
1y Target Est: 6.60
52wk Range: 1.70 – 5.30
Avg Vol (3m): 713,782
Market Cap: 252.31M

Vical, Inc. (VICL) turned a profit in the third quarter after licensing a vaccine to Astellas Pharma, Japan. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Last updated by at .

  Recent Penny Stock News